The federal government of Australia will invest A$28.1 million ($20.9 million) into a new agency for the Health Portfolio, Genomics Australia, it has been announced.
This announcement complements other recent initiatives such as the Medicines Australia and AusBiotech’s joint Cell and Gene Therapy Catalyst program, the Industry Genomics Network Alliance (InGeNA) and the Omico Precision Oncology Screening Platform PrOSPECT, which was announced just last week.
"The establishment of Genomics Australia builds on Australia’s growing infrastructure that will support genomic research and medicine into the future"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze